Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase

J Clin Oncol. 2013 Mar 1;31(7):e111-3. doi: 10.1200/JCO.2012.42.1784. Epub 2013 Jan 14.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Argininosuccinate Synthase / deficiency
  • Argininosuccinate Synthase / genetics
  • Argininosuccinate Synthase / metabolism*
  • Asbestos / adverse effects
  • Cisplatin / administration & dosage
  • Clinical Trials as Topic
  • DNA Methylation*
  • Fatal Outcome
  • Fluorodeoxyglucose F18*
  • Glutamates / administration & dosage
  • Guanine / administration & dosage
  • Guanine / analogs & derivatives
  • Humans
  • Hydrolases / therapeutic use*
  • Male
  • Mesothelioma / complications
  • Mesothelioma / diagnostic imaging
  • Mesothelioma / drug therapy*
  • Mesothelioma / enzymology*
  • Mesothelioma / etiology
  • Middle Aged
  • Mutation
  • Occupational Exposure / adverse effects
  • Pemetrexed
  • Pleural Effusion, Malignant / etiology
  • Pleural Neoplasms / complications
  • Pleural Neoplasms / diagnostic imaging
  • Pleural Neoplasms / drug therapy*
  • Pleural Neoplasms / enzymology*
  • Pleural Neoplasms / etiology
  • Polyethylene Glycols / therapeutic use*
  • Positron-Emission Tomography / methods*
  • Promoter Regions, Genetic*
  • Radiopharmaceuticals

Substances

  • Glutamates
  • Radiopharmaceuticals
  • Pemetrexed
  • Fluorodeoxyglucose F18
  • Asbestos
  • Polyethylene Glycols
  • Guanine
  • Hydrolases
  • ADI PEG20
  • Argininosuccinate Synthase
  • Cisplatin